GlassScriptPhysician profile
Bronislava Shafran
NPI 1356339493
$247.86
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $140 · 2021: $73.00 · 2022: $34.88.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $116.91 | 2019 | |
| Genzyme Corporation | $73.00 | 2021 | |
| Amneal Pharmaceuticals LLC | $23.07 | 2019 | |
| Sunovion Pharmaceuticals INC. | $21.87 | 2022 | |
| Abbvie INC. | $13.01 | 2022 |
3 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bronislava Shafran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.